Go Pro
→ Someone just dumped the biggest gold fund. (From Behind the Markets) (Ad)tc pixel Free OPRX Stock Alerts

OptimizeRx (OPRX) Financials

OptimizeRx logo
$8.01 -0.22 (-2.67%)
Closing price 08/19/2026 04:00 PM Eastern
Extended Trading
$8.01 0.00 (-0.06%)
As of 04:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for OptimizeRx

Annual Income Statements for OptimizeRx

This table shows OptimizeRx's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -0.60 -1.54 -2.10 0.23 -3.14 -2.28 0.38 -11 -18 -20 5.13
Consolidated Net Income / (Loss)		 -0.60 -1.54 -2.10 0.23 -3.14 -2.21 0.38 -11 -18 -20 5.13
Net Income / (Loss) Continuing Operations		 -0.60 -1.54 -2.10 0.23 -3.14 -2.28 0.38 -11 -18 -20 5.13
Total Pre-Tax Income 		-0.60 -1.54 -2.10 0.23 -4.04 -2.21 0.38 -11 -25 -19 6.95
Total Operating Income		 -0.60 -1.58 -2.13 0.18 -3.69 -2.14 0.36 -12 -26 -14 12
Total Gross Profit		 3.60 4.34 5.95 12 15 24 36 39 43 59 74
Total Revenue		 3.60 4.34 5.95 21 25 43 61 62 72 92 109
Operating Revenue		 3.60 4.34 5.95 21 25 43 61 62 72 92 109
Total Cost of Revenue		 0.00 0.00 0.00 9.00 9.16 19 26 23 29 33 36
Operating Cost of Revenue		 - - - 9.00 9.16 19 26 23 29 33 36
Total Operating Expenses		 4.20 5.92 8.08 12 19 26 35 51 67 73 62
Selling, General & Admin Expense		 3.28 5.08 6.86 9.19 16 21 28 33 44 50 50
Depreciation Expense		 0.33 0.24 0.32 0.32 1.28 2.08 2.09 2.02 2.40 4.33 4.33
Other Operating Expenses / (Income)		 0.58 0.56 0.90 2.52 2.26 3.17 - - - 11 6.96
Impairment Charge		 - - - - - - - 0.00 6.74 7.49 0.37
Total Other Income / (Expense), net		 0.00 0.04 0.03 0.05 -0.35 -0.14 0.02 0.85 -0.90 -5.68 -4.74
Interest Expense		 0.00 - - - - - - 0.00 1.45 6.16 5.29
Interest & Investment Income		 0.00 0.04 0.03 0.05 0.29 0.07 - 0.85 2.19 0.33 0.35
Other Income / (Expense), net		 - - - 0.00 -0.64 -0.21 0.02 0.00 -1.64 0.15 0.20
Income Tax Expense		 0.00 0.00 0.00 - -0.90 0.00 0.00 0.00 -7.60 0.73 1.82
Basic Earnings per Share		 ($0.02) ($0.05) ($0.21) - ($0.23) ($0.15) $0.02 ($0.64) ($1.03) ($1.10) $0.28
Weighted Average Basic Shares Outstanding		 24.56M 29.71M 9.82M 10.83M 13.39M 14.83M 17.23M 17.78M 17.12M 18.29M 18.56M
Diluted Earnings per Share		 ($0.02) ($0.05) ($0.21) - ($0.23) ($0.15) $0.02 ($0.64) ($1.03) ($1.10) $0.27
Weighted Average Diluted Shares Outstanding		 29.03M 29.71M 9.82M 11.86M 13.39M 14.83M 17.69M 17.78M 17.12M 18.29M 19.00M
Weighted Average Basic & Diluted Shares Outstanding		 29.03M 29.71M 29.46M 12.10M 14.64M 16.81M 17.88M 17.10M - - 18.76M

Quarterly Income Statements for OptimizeRx

This table shows OptimizeRx's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Total Costs & Expenses		 - - - - - - 26 - - - 21
Net Income / (Loss) Attributable to Common Shareholders		 -4.14 -6.90 -4.01 -9.12 -0.08 -2.20 1.53 0.78 5.02 -0.50 -0.69
Consolidated Net Income / (Loss)		 -4.14 -6.90 -4.01 -9.12 -0.08 -2.20 1.53 0.78 5.02 -0.50 -0.70
Net Income / (Loss) Continuing Operations		 -4.14 -6.90 -4.01 -9.12 -0.08 -2.20 1.53 0.78 5.02 -0.50 -0.70
Total Pre-Tax Income 		-12 -6.56 -5.10 -9.94 2.21 -3.27 1.73 1.05 7.47 -0.64 -1.10
Total Operating Income		 -11 -5.03 -3.75 -8.56 3.63 -2.10 3.21 2.05 8.57 0.40 -0.09
Total Gross Profit		 18 12 12 13 22 13 19 18 24 15 16
Total Revenue		 28 20 19 21 32 22 29 26 32 20 21
Operating Revenue		 28 20 19 21 32 22 29 26 32 20 21
Total Cost of Revenue		 11 7.49 7.11 7.86 10 8.58 11 8.55 8.14 4.91 4.82
Operating Cost of Revenue		 11 7.49 7.11 7.86 10 8.58 11 8.55 8.14 4.91 4.82
Total Operating Expenses		 27 17 15 22 18 15 15 15 16 15 16
Selling, General & Admin Expense		 5.18 16 14 13 5.83 4.56 3.91 14 7.12 3.51 3.70
Marketing Expense		 - - - - - 4.99 5.87 - - 4.73 5.53
Research & Development Expense		 - - - - - 3.25 3.09 - - 3.40 3.27
Depreciation Expense		 1.01 1.07 1.07 1.10 1.09 1.09 1.07 1.08 1.08 1.06 1.06
Other Operating Expenses / (Income)		 - - - - - 1.56 1.49 - - 1.83 2.21
Total Other Income / (Expense), net		 -2.98 -1.53 -1.35 -1.38 -1.43 -1.17 -1.48 -1.00 -1.10 -1.04 -1.01
Interest Expense		 - 1.55 1.53 1.52 1.56 1.30 1.60 1.15 1.24 1.16 1.13
Interest & Investment Income		 0.12 0.02 0.11 0.11 0.10 0.09 0.09 0.09 0.08 0.08 0.08
Other Income / (Expense), net		 - 0.00 0.08 0.04 - 0.04 0.04 0.06 0.06 0.04 0.04
Income Tax Expense		 -7.63 0.34 -1.09 -0.82 2.29 -1.07 0.20 0.27 2.45 -0.15 -0.39
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - - - - - 0.00 - - - -0.01
Basic Earnings per Share		 ($0.25) ($0.38) ($0.22) ($0.50) - ($0.12) $0.08 $0.04 $0.28 ($0.03) ($0.04)
Weighted Average Basic Shares Outstanding		 17.12M 18.17M 18.26M 18.32M 18.29M 18.47M 18.51M 18.58M 18.56M 18.76M 18.79M
Diluted Earnings per Share		 ($0.25) ($0.38) ($0.22) ($0.50) - ($0.12) $0.08 $0.04 $0.27 ($0.03) ($0.04)
Weighted Average Diluted Shares Outstanding		 17.12M 18.17M 18.26M 18.32M 18.29M 18.47M 19.02M 19.46M 19.00M 18.76M 18.79M
Weighted Average Basic & Diluted Shares Outstanding		 0.00 18.27M 18.32M - 0.00 18.50M 18.57M 18.64M 18.76M 18.77M 18.84M

Annual Cash Flow Statements for OptimizeRx

This table details how cash moves in and out of OptimizeRx's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 4.76 -1.17 -1.91 3.79 9.94 -8.34 74 -66 -4.36 -0.47 9.99
Net Cash From Operating Activities		 0.52 -0.47 -1.48 0.79 -1.66 -6.31 0.73 11 -7.24 4.89 19
Net Cash From Continuing Operating Activities		 0.52 -0.47 -1.48 0.79 -1.66 -6.31 0.73 11 -7.24 4.89 19
Net Income / (Loss) Continuing Operations		 -0.60 -1.54 -2.10 0.23 -3.14 -2.21 0.38 -11 -18 -20 5.13
Consolidated Net Income / (Loss)		 -0.60 -1.54 -2.10 0.23 -3.14 -2.21 0.38 -11 -18 -20 5.13
Depreciation Expense		 0.33 0.24 0.32 0.32 1.18 1.97 1.97 2.02 2.40 4.33 4.33
Amortization Expense		 - - - - - - - 0.00 0.21 0.84 1.11
Non-Cash Adjustments To Reconcile Net Income		 1.47 0.83 -0.03 3.25 1.26 3.48 5.57 16 23 19 5.36
Changes in Operating Assets and Liabilities, net		 -0.69 0.01 0.33 -3.00 -0.95 -9.55 -7.19 3.96 -16 1.12 2.78
Net Cash From Investing Activities		 -0.10 -0.35 -0.04 -5.69 -11 -0.12 -0.49 -58 -25 -0.45 0.07
Net Cash From Continuing Investing Activities		 -0.10 -0.35 -0.04 -5.69 -11 -0.12 -0.49 -58 -25 -0.45 0.07
Purchase of Property, Plant & Equipment		 -0.00 -0.18 -0.04 -0.03 -0.09 -0.11 -0.46 -0.24 -0.87 -0.45 0.07
Net Cash From Financing Activities		 4.35 -0.36 -0.39 8.69 22 -1.90 74 -19 28 -4.91 -8.80
Net Cash From Continuing Financing Activities		 4.35 -0.36 -0.39 8.69 22 -1.90 74 -19 28 -4.91 -8.80
Repayment of Debt		 - - - - - - - 0.00 -1.71 -4.00 -8.00
Other Financing Activities, net		 - - 0.00 0.52 0.88 -1.90 3.25 1.07 -0.28 -0.91 -0.80
Cash Interest Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.21 6.20 4.18
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.05 0.16 1.76

Quarterly Cash Flow Statements for OptimizeRx

This table details how cash moves in and out of OptimizeRx's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 3.93 1.33 -0.22 1.17 -2.75 3.19 0.01 2.93 3.85 -3.20 3.93
Net Cash From Operating Activities		 -6.26 2.12 0.78 1.79 0.20 3.86 4.56 3.20 7.09 -0.47 8.61
Net Cash From Continuing Operating Activities		 -6.26 2.12 0.78 1.79 0.20 3.86 4.56 3.20 7.09 -0.47 8.61
Net Income / (Loss) Continuing Operations		 -4.14 -6.90 -4.01 -9.12 -0.08 -2.20 1.53 0.78 5.02 -0.50 -0.70
Consolidated Net Income / (Loss)		 -4.14 -6.90 -4.01 -9.12 -0.08 -2.20 1.53 0.78 5.02 -0.50 -0.70
Depreciation Expense		 1.01 1.07 1.07 1.10 1.09 1.09 1.07 1.08 1.08 1.06 1.06
Amortization Expense		 0.21 0.18 0.18 0.18 0.29 0.17 0.44 0.17 0.33 0.36 0.28
Non-Cash Adjustments To Reconcile Net Income		 12 0.46 2.18 11 3.01 -1.75 2.34 1.69 3.09 1.83 -0.07
Changes in Operating Assets and Liabilities, net		 -15 7.30 1.35 -1.57 -4.12 6.55 -0.82 -0.53 -2.42 -3.22 8.04
Net Cash From Investing Activities		 -26 -0.15 -0.09 -0.09 -0.12 -0.08 -0.04 -0.01 0.21 -0.02 -0.04
Net Cash From Continuing Investing Activities		 -26 -0.15 -0.09 -0.09 -0.12 -0.08 -0.04 -0.01 0.21 -0.02 -0.04
Purchase of Property, Plant & Equipment		 0.77 -0.15 -0.09 -0.09 -0.12 -0.08 -0.04 -0.01 0.21 -0.02 -0.04
Net Cash From Financing Activities		 36 -0.64 -0.92 -0.53 -2.82 -0.59 -4.51 -0.26 -3.45 -2.71 -4.66
Net Cash From Continuing Financing Activities		 36 -0.64 -0.92 -0.53 -2.82 -0.59 -4.51 -0.26 -3.45 -2.71 -4.66
Repayment of Debt		 -1.41 -0.50 -0.50 -0.50 -2.50 -0.50 -4.50 -0.50 -2.50 -2.69 -29
Other Financing Activities, net		 -0.13 -0.14 -0.42 -0.03 -0.32 -0.09 -0.01 0.24 -0.95 -0.02 -0.05
Cash Interest Paid		 1.21 1.35 1.36 1.37 2.12 1.12 1.17 0.98 0.92 0.80 0.77
Cash Income Taxes Paid		 0.05 0.02 0.09 -0.11 0.16 0.00 1.09 -0.08 0.75 0.01 1.21

Annual Balance Sheets for OptimizeRx

This table presents OptimizeRx's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 12 11 9.76 25 57 60 141 135 183 171 177
Total Current Assets		 11 10 8.81 16 27 33 115 99 54 54 65
Cash & Equivalents		 8.21 7.03 5.12 8.91 19 11 85 18 14 13 23
Accounts Receivable		 2.85 3.06 3.43 6.46 7.42 18 25 22 36 38 38
Prepaid Expenses		 0.07 0.08 0.26 0.36 0.87 4.46 5.63 2.28 3.19 2.38 2.85
Current Deferred & Refundable Income Taxes		 - - - - - - - 0.00 1.04 0.00 0.75
Plant, Property, & Equipment, net		 0.01 0.17 0.17 0.15 0.18 0.15 0.14 0.14 0.15 0.15 0.11
Total Noncurrent Assets		 1.18 1.13 0.79 9.17 29 27 51 36 129 117 112
Goodwill		 - - 0.00 3.68 15 15 15 23 78 71 71
Intangible Assets		 1.17 1.12 0.78 5.15 5.15 4.52 3.90 3.38 34 37 41
Other Noncurrent Operating Assets		 0.01 0.01 0.01 0.34 9.43 8.06 33 9.88 16 8.84 0.43
Total Liabilities & Shareholders' Equity		 12 11 9.76 25 57 60 141 135 183 171 177
Total Liabilities		 3.37 3.67 3.54 6.60 12 10 9.61 8.54 57 54 49
Total Current Liabilities		 3.37 3.67 3.54 4.23 6.11 10 9.37 8.40 18 19 21
Short-Term Debt		 - - - - - - - 0.00 2.00 2.00 4.26
Accounts Payable		 0.78 0.37 0.46 0.41 0.49 0.62 0.61 1.55 2.23 2.16 1.64
Accrued Expenses		 0.01 0.29 0.95 1.30 1.80 2.42 2.90 2.60 7.71 8.49 12
Current Deferred Revenue		 0.23 0.39 0.51 0.61 0.58 0.29 1.39 0.16 0.17 0.47 0.50
Other Current Liabilities		 2.36 2.62 1.62 1.91 3.23 6.70 4.47 4.08 5.73 5.22 3.28
Total Noncurrent Liabilities		 0.00 0.00 0.00 2.37 5.67 0.33 0.24 0.14 39 36 27
Long-Term Debt		 - - - - - - - 0.00 34 31 21
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - - 0.00 4.34 4.49 5.71
Other Noncurrent Operating Liabilities		 - - 0.00 2.37 5.67 0.33 0.24 0.14 0.37 0.21 0.23
Commitments & Contingencies		 - - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 8.94 7.81 6.22 18 45 50 131 126 127 117 128
Total Preferred & Common Equity		 8.94 7.81 6.22 18 45 50 131 126 127 117 128
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 8.94 7.81 6.22 18 45 50 131 126 127 117 128
Common Stock		 32 34 35 49 78 86 167 173 191 201 208
Retained Earnings		 -27 -28 -30 -30 -33 -36 -35 -47 -64 -84 -79
Treasury Stock		 - - - - - - 0.00 -0.00 -0.00 - -0.00
Accumulated Other Comprehensive Income / (Loss)		 - - - - - - - - - - 0.00

Quarterly Balance Sheets for OptimizeRx

This table presents OptimizeRx's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 124 176 173 165 168 169 170 167 164
Total Current Assets		 87 48 46 47 52 54 56 56 54
Cash & Equivalents		 9.92 15 15 16 17 17 20 20 24
Accounts Receivable		 21 30 25 26 33 34 32 32 25
Prepaid Expenses		 3.01 2.39 4.65 4.39 2.31 3.34 2.83 3.14 2.93
Current Deferred & Refundable Income Taxes		 - 1.04 1.84 0.06 0.11 0.65 1.75 0.87 2.33
Plant, Property, & Equipment, net		 0.15 0.15 0.17 0.16 0.15 0.13 0.12 0.11 0.12
Total Noncurrent Assets		 36 128 127 118 116 115 114 111 110
Goodwill		 23 78 78 71 71 71 71 71 71
Intangible Assets		 4.92 48 47 38 37 36 35 33 39
Other Noncurrent Operating Assets		 8.00 0.53 0.47 9.17 8.46 8.37 7.96 6.95 0.47
Total Liabilities & Shareholders' Equity		 124 176 173 165 168 169 170 167 164
Total Liabilities		 7.82 54 52 51 51 50 48 38 33
Total Current Liabilities		 7.70 17 15 15 18 21 18 10 9.71
Short-Term Debt		 - 3.50 3.30 2.00 3.30 3.30 3.30 2.00 1.25
Accounts Payable		 0.69 1.67 2.98 2.75 3.38 1.98 2.04 3.07 1.32
Accrued Expenses		 3.11 7.28 5.31 5.56 9.28 12 10 3.59 5.39
Current Deferred Revenue		 0.19 0.90 1.05 0.79 0.51 0.48 0.40 0.67 0.71
Other Current Liabilities		 3.71 3.05 2.31 3.41 1.88 2.80 2.54 1.13 1.04
Total Noncurrent Liabilities		 0.12 37 37 36 33 29 30 27 24
Long-Term Debt		 - 32 32 33 29 25 25 21 18
Noncurrent Deferred & Payable Income Tax Liabilities		 - 4.34 4.34 2.71 3.79 3.46 4.49 5.66 5.52
Other Noncurrent Operating Liabilities		 0.12 - - 0.24 0.17 0.34 0.30 0.20 0.25
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 116 123 121 114 116 119 122 130 131
Total Preferred & Common Equity		 116 123 121 114 116 119 122 130 131
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 116 123 121 114 116 119 122 130 131
Common Stock		 176 194 196 199 203 204 207 209 212
Retained Earnings		 -60 -71 -75 -84 -87 -85 -84 -80 -80
Treasury Stock		 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00
Accumulated Other Comprehensive Income / (Loss)		 - - - - - - - - 0.01

Annual Metrics And Ratios for OptimizeRx

This table displays calculated financial ratios and metrics derived from OptimizeRx's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 29,018,425.00 29,672,132.00 29,275,117.00 12,013,682.00 14,173,850.00 15,108,646.00 17,769,544.00 17,152,717.00 18,152,478.00 - 18,640,652.00
DEI Adjusted Shares Outstanding		 29,018,425.00 29,672,132.00 29,275,117.00 12,013,682.00 14,173,850.00 15,108,646.00 17,769,544.00 17,152,717.00 18,152,478.00 - 18,640,652.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.02 -0.05 -0.07 0.02 -0.22 -0.15 0.02 -0.67 -0.97 - 0.28
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 9.66% 20.61% 37.16% 256.24% 15.99% 76.08% 41.51% 1.89% 14.53% 28.81% 18.78%
EBITDA Growth		 65.43% -410.99% -34.11% 127.51% -734.96% 88.06% 722.53% -538.20% -147.66% 67.01% 306.53%
EBIT Growth		 41.79% -164.73% -34.68% 108.46% -2,503.00% 45.77% 116.11% -3,350.84% -128.17% 51.67% 187.73%
NOPAT Growth		 41.79% -164.73% -34.68% 112.08% -1,535.33% 42.19% 124.16% -2,482.59% -114.81% 48.09% 190.00%
Net Income Growth		 41.96% -158.63% -36.70% 110.76% -1,488.41% 29.77% 117.13% -3,125.41% -53.57% -14.48% 125.52%
EPS Growth		 50.00% -150.00% -320.00% 0.00% 0.00% 34.78% 113.33% -3,300.00% -60.94% -6.80% 124.55%
Operating Cash Flow Growth		 1,014.13% -190.46% -217.58% 153.56% -309.55% -279.96% 111.51% 1,367.43% -167.96% 167.53% 282.80%
Free Cash Flow Firm Growth		 100.75% -11,602.23% -57.56% -356.35% -130.46% 21.57% -118.23% 136.35% -1,074.00% 102.52% 398.08%
Invested Capital Growth		 -36.81% 5.80% 41.21% 769.28% 172.51% 51.70% 83.56% -28.24% 186.57% -8.39% -4.27%
Revenue Q/Q Growth		 30.87% 4.90% 50.44% 23.65% 3.36% 26.40% 6.77% -1.04% 13.88% 4.48% -0.07%
EBITDA Q/Q Growth		 -170.62% 2.70% 8.09% 45.50% -446.96% 90.14% -24.01% -20.26% -75.66% 63.96% 40.29%
EBIT Q/Q Growth		 -1,316.15% 2.95% 5.70% 171.80% -193.35% 59.60% -65.52% -17.18% -71.74% 52.07% 71.44%
NOPAT Q/Q Growth		 -951.30% 2.95% 5.70% 171.80% -146.15% 63.25% -67.07% -13.75% -61.68% 51.53% 6,422.76%
Net Income Q/Q Growth		 -1,280.97% 3.86% 5.21% 128.17% -147.89% 60.23% -65.99% -9.05% -27.75% 16.81% 15,451.52%
EPS Q/Q Growth		 -300.00% -25.00% -31.25% 0.00% 0.00% 61.54% -71.43% -12.28% -27.16% 18.52% 0.00%
Operating Cash Flow Q/Q Growth		 -32.29% -1,887.14% 22.13% 687.10% -315.16% -20.94% 236.47% 63.51% -497.48% 412.17% 58.27%
Free Cash Flow Firm Q/Q Growth		 -98.27% -112.30% 15.90% -220.93% -104.05% 44.13% -441.84% 171.50% -829.43% 102.86% 397.98%
Invested Capital Q/Q Growth		 -31.01% 66.80% 5.66% 159.28% 117.34% 13.88% 73.43% 2.36% 187.71% 2.11% -0.18%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 57.56% 62.77% 55.65% 58.14% 62.40% 59.98% 64.45% 67.25%
EBITDA Margin		 -7.32% -31.02% -30.33% 2.34% -12.82% -0.87% 3.82% -16.44% -35.56% -9.11% 15.83%
Operating Margin		 -16.60% -36.44% -35.78% 0.85% -15.02% -4.93% 0.59% -19.68% -36.91% -14.88% 10.69%
EBIT Margin		 -16.60% -36.44% -35.78% 0.85% -17.60% -5.42% 0.62% -19.68% -39.21% -14.71% 10.87%
Profit (Net Income) Margin		 -16.54% -35.47% -35.35% 1.07% -12.78% -5.10% 0.62% -18.32% -24.56% -21.83% 4.69%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 77.78% 100.00% 100.00% 100.00% 69.81% 103.74% 73.84%
Interest Burden Percent		 99.62% 97.32% 98.78% 125.65% 93.35% 94.02% 100.00% 93.07% 89.73% 143.02% 58.45%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 26.16%
Return on Invested Capital (ROIC)		 -44.06% -146.39% -159.00% 3.39% -14.54% -4.57% 0.65% -13.83% -18.40% -6.72% 6.47%
ROIC Less NNEP Spread (ROIC-NNEP)		 -41.03% -140.72% -148.91% 2.73% -10.53% 0.29% 0.60% -9.57% -21.94% -57.02% -25.74%
Return on Net Nonoperating Assets (RNNOA)		 35.28% 128.02% 129.01% -1.55% 4.62% -0.09% -0.23% 4.95% 4.49% -9.79% -2.28%
Return on Equity (ROE)		 -8.78% -18.37% -29.99% 1.83% -9.93% -4.65% 0.42% -8.88% -13.90% -16.51% 4.18%
Cash Return on Invested Capital (CROIC)		 1.05% -152.02% -193.17% -155.35% -107.16% -45.65% -58.29% 19.06% -114.92% 2.04% 10.83%
Operating Return on Assets (OROA)		 -6.18% -13.29% -20.05% 1.03% -10.60% -4.01% 0.38% -8.92% -17.64% -7.65% 6.83%
Return on Assets (ROA)		 -6.15% -12.94% -19.81% 1.30% -7.69% -3.77% 0.38% -8.30% -11.05% -11.34% 2.95%
Return on Common Equity (ROCE)		 -8.78% -18.37% -29.99% 1.83% -9.93% -4.65% 0.42% -8.88% -13.90% -16.51% 4.18%
Return on Equity Simple (ROE_SIMPLE)		 -6.66% -19.70% -33.82% 1.23% -7.00% -4.42% 0.29% -9.07% -13.88% -17.19% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.42 -1.11 -1.49 0.18 -2.59 -1.49 0.36 -8.60 -18 -9.59 8.63
NOPAT Margin		 -11.62% -25.51% -25.05% 0.85% -10.51% -3.45% 0.59% -13.78% -25.84% -10.41% 7.89%
Net Nonoperating Expense Percent (NNEP)		 -3.04% -5.67% -10.09% 0.66% -4.01% -4.85% 0.05% -4.26% 3.54% 50.30% 32.21%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -11.35% -6.40% 5.61%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 42.44% 37.23% 44.35% 41.86% 37.60% 40.02% 35.55% 32.75%
SG&A Expenses to Revenue		 91.17% 116.98% 115.17% 43.33% 63.38% 48.47% 45.19% 53.63% 61.94% 54.05% 45.92%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 116.60% 136.44% 135.78% 56.71% 77.78% 60.58% 57.56% 82.08% 93.90% 79.33% 56.57%
Earnings before Interest and Taxes (EBIT)		 -0.60 -1.58 -2.13 0.18 -4.33 -2.35 0.38 -12 -28 -14 12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.26 -1.35 -1.81 0.50 -3.15 -0.38 2.34 -10 -25 -8.39 17
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.22 4.94 2.05 7.05 3.06 9.25 8.36 2.37 1.94 0.76 1.82
Price to Tangible Book Value (P/TBV)		 4.86 5.77 2.35 13.52 5.51 15.04 9.75 2.99 17.51 6.21 8.29
Price to Revenue (P/Rev)		 10.49 8.90 2.14 6.14 5.59 10.67 17.93 4.78 3.43 0.97 2.13
Price to Earnings (P/E)		 0.00 0.00 0.00 574.95 0.00 0.00 2,906.16 0.00 0.00 0.00 45.39
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.17% 0.00% 0.00% 0.03% 0.00% 0.00% 0.00% 2.20%
Enterprise Value to Invested Capital (EV/IC)		 40.18 40.62 6.96 12.70 4.56 11.44 14.00 4.32 1.80 0.79 1.80
Enterprise Value to Revenue (EV/Rev)		 8.21 7.28 1.28 5.72 4.82 10.42 16.54 3.60 3.74 1.18 2.15
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 244.09 0.00 0.00 432.74 0.00 0.00 0.00 13.58
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 672.97 0.00 0.00 2,682.18 0.00 0.00 0.00 19.78
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 672.97 0.00 0.00 2,808.29 0.00 0.00 0.00 27.24
Enterprise Value to Operating Cash Flow (EV/OCF)		 57.33 0.00 0.00 152.95 0.00 0.00 1,396.72 21.08 0.00 22.16 12.57
Enterprise Value to Free Cash Flow (EV/FCFF)		 2,954.71 0.00 0.00 0.00 0.00 0.00 0.00 18.95 0.00 37.31 16.26
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.29 0.28 0.20
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.27 0.26 0.17
Financial Leverage		 -0.86 -0.91 -0.87 -0.57 -0.44 -0.31 -0.38 -0.52 -0.20 0.17 0.09
Leverage Ratio		 1.43 1.42 1.51 1.41 1.29 1.23 1.11 1.07 1.26 1.46 1.42
Compound Leverage Factor		 1.42 1.38 1.50 1.77 1.20 1.16 1.11 1.00 1.13 2.08 0.83
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 22.26% 21.90% 16.68%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.23% 1.34% 2.76%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 21.03% 20.57% 13.91%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 77.74% 78.10% 83.32%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.42 -3.91 1.48
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.88 -2.32 0.13
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.35 -3.67 1.24
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.96 -3.42 2.97
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.21 -2.03 0.27
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.85 -3.21 2.48
Altman Z-Score		 4.57 3.48 -1.66 11.57 6.81 26.99 69.63 21.47 2.22 0.82 3.38
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.30 2.78 2.49 3.72 4.44 3.28 12.29 11.74 3.04 2.89 3.04
Quick Ratio		 3.28 2.75 2.41 3.63 4.30 2.83 11.69 11.47 2.80 2.77 2.87
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.01 -1.15 -1.81 -8.27 -19 -15 -33 12 -115 2.90 14
Operating Cash Flow to CapEx		 25,176.44% -261.14% -3,503.14% 2,306.49% -1,893.36% -5,594.66% 156.31% 4,356.34% -840.88% 1,086.44% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -79.40 0.47 2.73
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -4.98 0.79 3.54
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -5.57 0.72 3.55
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.37 0.36 0.56 1.22 0.60 0.74 0.61 0.45 0.45 0.52 0.63
Accounts Receivable Turnover		 1.45 1.47 1.83 4.29 3.55 3.42 2.87 2.66 2.45 2.47 2.88
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 312.21 47.20 34.92 133.95 151.21 266.65 418.85 444.06 499.37 616.23 854.91
Accounts Payable Turnover		 0.00 0.00 0.00 20.73 20.26 34.57 41.88 21.78 15.16 14.94 18.90
Days Sales Outstanding (DSO)		 250.93 248.43 199.01 85.10 102.95 106.62 127.10 137.22 149.04 147.51 126.69
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 17.61 18.01 10.56 8.71 16.76 24.08 24.43 19.31
Cash Conversion Cycle (CCC)		 250.93 248.43 199.01 67.49 84.93 96.06 118.38 120.46 124.96 123.09 107.38
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.73 0.78 1.10 9.54 26 39 72 52 149 136 131
Invested Capital Turnover		 3.79 5.74 6.35 3.99 1.38 1.32 1.10 1.00 0.71 0.65 0.82
Increase / (Decrease) in Invested Capital		 -0.43 0.04 0.32 8.45 16 13 33 -20 97 -12 -5.83
Enterprise Value (EV)		 30 32 7.64 121 119 452 1,014 225 267 108 235
Market Capitalization		 38 39 13 130 137 462 1,099 299 245 89 233
Book Value per Share		 $0.31 $0.26 $0.21 $1.54 $3.17 $3.31 $7.39 $7.35 $6.97 $6.40 $6.88
Tangible Book Value per Share		 $0.27 $0.23 $0.19 $0.80 $1.76 $2.03 $6.34 $5.83 $0.77 $0.78 $1.51
Total Capital		 8.94 7.81 6.22 18 45 50 131 126 163 150 154
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 36 33 26
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 34 31 21
Net Debt		 -8.21 -7.03 -5.12 -8.91 -19 -11 -85 -74 22 19 2.31
Capital Expenditures (CapEx)		 0.00 0.18 0.04 0.03 0.09 0.11 0.46 0.24 0.86 0.45 -0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.45 -0.53 0.14 2.59 2.18 12 21 16 25 24 24
Debt-free Net Working Capital (DFNWC)		 7.75 6.51 5.27 12 21 23 106 90 38 37 48
Net Working Capital (NWC)		 7.75 6.51 5.27 12 21 23 106 90 36 35 43
Net Nonoperating Expense (NNE)		 0.18 0.43 0.61 -0.05 0.56 0.71 -0.02 2.83 -0.92 11 3.50
Net Nonoperating Obligations (NNO)		 -8.21 -7.03 -5.12 -8.91 -19 -11 -59 -74 22 19 2.31
Total Depreciation and Amortization (D&A)		 0.33 0.24 0.32 0.32 1.18 1.97 1.97 2.02 2.61 5.16 5.44
Debt-free, Cash-free Net Working Capital to Revenue		 -12.61% -12.11% 2.40% 12.20% 8.87% 28.43% 34.36% 25.68% 34.39% 25.98% 22.24%
Debt-free Net Working Capital to Revenue		 215.48% 149.98% 88.46% 54.23% 85.51% 52.71% 172.52% 144.40% 53.76% 40.51% 43.60%
Net Working Capital to Revenue		 215.48% 149.98% 88.46% 54.23% 85.51% 52.71% 172.52% 144.40% 50.96% 38.34% 39.71%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.02) ($0.05) ($0.07) $0.02 $0.00 ($0.15) $0.00 ($0.64) ($1.03) ($1.10) $0.28
Adjusted Weighted Average Basic Shares Outstanding		 24.56M 29.71M 29.32M 10.83M 13.39M 14.83M 0.00 17.78M 17.12M 18.29M 18.56M
Adjusted Diluted Earnings per Share		 ($0.02) ($0.05) ($0.07) $0.02 $0.00 ($0.15) $0.00 ($0.64) ($1.03) ($1.10) $0.27
Adjusted Weighted Average Diluted Shares Outstanding		 29.03M 29.72M 29.32M 11.86M 13.39M 14.83M 0.00 17.78M 17.12M 18.29M 19.00M
Adjusted Basic & Diluted Earnings per Share		 ($0.02) ($0.05) ($0.07) $0.02 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 29.03M 29.72M 29.46M 12.10M 14.64M 16.81M 0.00 17.10M 0.00 0.00 18.76M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.42 -1.07 -1.49 0.13 -2.59 -1.49 4.10 2.42 -4.16 3.68 8.91
Normalized NOPAT Margin		 -11.62% -24.70% -25.05% 0.59% -10.51% -3.45% 6.68% 3.87% -5.82% 3.99% 8.14%
Pre Tax Income Margin		 -16.54% -35.47% -35.35% 1.07% -16.43% -5.10% 0.62% -18.32% -35.18% -21.04% 6.35%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -19.29 -2.20 2.25
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -12.71 -1.56 1.63
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -19.88 -2.27 2.26
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -13.30 -1.63 1.64
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -52.42% -18.54% 0.00% 0.00% 0.00% 0.00% -175.06% -42.82% 0.00% 0.00%

Quarterly Metrics And Ratios for OptimizeRx

This table displays calculated financial ratios and metrics derived from OptimizeRx's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 18,152,478.00 18,152,478.00 18,152,478.00 18,152,478.00 - 18,152,478.00 18,495,111.00 18,565,033.00 18,640,652.00 18,762,203.00 18,765,075.00
DEI Adjusted Shares Outstanding		 18,152,478.00 18,152,478.00 18,152,478.00 18,152,478.00 - 18,152,478.00 18,495,111.00 18,565,033.00 18,640,652.00 18,762,203.00 18,765,075.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.23 -0.38 -0.22 -0.50 - -0.12 0.08 0.04 0.27 -0.03 -0.04
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 44.34% 51.43% 36.14% 30.48% 13.91% 11.37% 55.19% 22.33% -0.24% -9.50% -29.77%
EBITDA Growth		 -1,246.89% 42.72% 44.84% -134.76% 151.61% 78.97% 295.91% 146.46% 98.44% 333.46% -72.85%
EBIT Growth		 -828.33% 28.80% 24.23% -139.91% 133.23% 58.98% 187.81% 124.78% 134.90% 121.04% -101.54%
NOPAT Growth		 -1,165.35% 28.80% 22.69% -140.98% 98.30% 58.20% 208.68% 125.40% 4,525.24% 118.84% -102.17%
Net Income Growth		 -1,171.19% -7.83% 3.68% -218.46% 98.09% 68.13% 138.22% 108.54% 6,454.43% 77.49% -145.89%
EPS Growth		 -733.33% -2.70% 8.33% -194.12% 0.00% 68.42% 136.36% 108.00% 0.00% 75.00% -150.00%
Operating Cash Flow Growth		 -323.22% 2,562.79% 133.01% 21.59% 103.16% 82.44% 483.25% 78.78% 3,479.80% -112.09% 88.80%
Free Cash Flow Firm Growth		 -627.01% -634.93% -2,889.73% -2,426.18% 111.82% 109.79% 114.52% 104.89% -6.33% -103.40% -61.59%
Invested Capital Growth		 186.57% 184.68% 166.59% 158.12% -8.39% -7.62% -7.32% -2.07% -4.27% 0.45% -3.91%
Revenue Q/Q Growth		 73.72% -30.60% -4.46% 13.27% 51.65% -32.15% 33.14% -10.71% 23.68% -38.45% 3.33%
EBITDA Q/Q Growth		 -214.84% 61.11% 36.03% -199.71% 169.21% -115.73% 686.99% -28.92% 197.92% -81.50% -30.44%
EBIT Q/Q Growth		 -207.82% 54.02% 26.94% -132.01% 142.63% -156.17% 255.47% -34.53% 308.52% -94.97% -111.52%
NOPAT Q/Q Growth		 -207.82% 54.02% 25.45% -128.38% 97.83% -1,031.15% 292.73% -46.62% 278.12% -95.18% -122.22%
Net Income Q/Q Growth		 -44.57% -66.56% 41.90% -127.64% 99.13% -2,683.54% 169.67% -49.15% 544.42% -109.86% -42.02%
EPS Q/Q Growth		 -47.06% -52.00% 42.11% -127.27% 0.00% 0.00% 166.67% -50.00% 575.00% -111.11% -33.33%
Operating Cash Flow Q/Q Growth		 -524.85% 133.84% -63.08% 129.03% -88.94% 1,851.52% 18.04% -29.80% 121.36% -106.59% 1,943.90%
Free Cash Flow Firm Q/Q Growth		 -2,908.49% 7.91% 5.51% 3.51% 114.08% -23.77% 40.29% -67.51% 169.78% -102.77% 1,680.86%
Invested Capital Q/Q Growth		 187.71% -3.92% -1.12% -5.56% 2.11% -3.11% -0.80% -0.21% -0.18% 1.67% -5.12%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 62.89% 61.98% 62.22% 63.10% 68.15% 60.85% 63.83% 67.20% 74.75% 75.25% 76.51%
EBITDA Margin		 -34.26% -19.20% -12.85% -34.01% 15.52% -3.63% 16.23% 12.92% 31.11% 9.35% 6.30%
Operating Margin		 -38.55% -25.54% -19.93% -40.18% 11.25% -9.59% 10.92% 7.86% 26.58% 2.00% -0.43%
EBIT Margin		 -38.55% -25.54% -19.53% -40.00% 11.25% -9.41% 11.05% 8.10% 26.76% 2.19% -0.24%
Profit (Net Income) Margin		 -14.60% -35.04% -21.31% -42.82% -0.24% -10.03% 5.25% 2.99% 15.57% -2.49% -3.43%
Tax Burden Percent		 35.18% 105.25% 78.65% 91.78% -3.58% 67.21% 89.43% 74.26% 67.18% 76.86% 64.14%
Interest Burden Percent		 107.64% 130.34% 138.70% 116.62% 60.73% 158.60% 53.10% 49.67% 86.60% -148.39% 2,192.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 103.58% 0.00% 10.57% 25.74% 32.82% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -19.21% -14.46% -11.93% -26.76% -0.26% -4.60% 7.51% 4.84% 14.63% 1.13% -0.23%
ROIC Less NNEP Spread (ROIC-NNEP)		 -32.79% -1.75% -5.38% -12.90% -0.02% -8.59% -0.66% -0.52% 7.86% -6.96% -19.23%
Return on Net Nonoperating Assets (RNNOA)		 6.72% 0.38% 0.96% 2.53% 0.00% -1.31% -0.09% -0.06% 0.70% -0.54% -0.52%
Return on Equity (ROE)		 -12.50% -14.09% -10.97% -24.23% -0.26% -5.91% 7.42% 4.78% 15.33% 0.59% -0.75%
Cash Return on Invested Capital (CROIC)		 -114.92% -113.66% -107.63% -109.66% 2.04% 2.44% 5.62% 2.20% 10.83% 7.19% 9.77%
Operating Return on Assets (OROA)		 -17.34% -12.97% -11.05% -24.40% 5.84% -5.16% 6.77% 5.29% 16.83% 1.40% -0.14%
Return on Assets (ROA)		 -6.57% -17.79% -12.05% -26.12% -0.13% -5.50% 3.21% 1.95% 9.79% -1.60% -2.03%
Return on Common Equity (ROCE)		 -12.50% -14.09% -10.97% -24.23% -0.26% -5.91% 7.42% 4.78% 15.33% 0.59% -0.75%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -14.74% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.66 -3.52 -2.62 -5.99 -0.13 -1.47 2.85 1.52 5.76 0.28 -0.06
NOPAT Margin		 -26.99% -17.88% -13.95% -28.13% -0.40% -6.71% 9.77% 5.84% 17.86% 1.40% -0.30%
Net Nonoperating Expense Percent (NNEP)		 13.58% -12.71% -6.55% -13.86% -0.24% 3.99% 8.17% 5.36% 6.77% 8.09% 19.00%
Return On Investment Capital (ROIC_SIMPLE)		 -4.70% -2.22% -1.67% -4.00% -0.09% -0.99% 1.93% 1.01% 3.74% 0.18% -0.04%
Cost of Revenue to Revenue		 37.11% 38.02% 37.78% 36.90% 31.85% 39.15% 36.17% 32.80% 25.25% 24.75% 23.49%
SG&A Expenses to Revenue		 18.24% 82.10% 76.44% 63.00% 18.03% 20.78% 49.23% 55.19% 22.09% 17.70% 18.06%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 14.83% 0.00% 0.00% 0.00% 17.14% 15.97%
Operating Expenses to Revenue		 93.89% 87.52% 82.14% 103.29% 56.90% 70.44% 52.91% 59.33% 48.18% 73.25% 76.94%
Earnings before Interest and Taxes (EBIT)		 -11 -5.03 -3.67 -8.52 3.63 -2.06 3.23 2.11 8.63 0.43 -0.05
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.72 -3.78 -2.42 -7.25 5.02 -0.80 4.74 3.37 10 1.86 1.29
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.94 1.80 1.51 1.24 0.76 1.38 2.15 3.26 1.82 0.91 0.82
Price to Tangible Book Value (P/TBV)		 17.51 0.00 0.00 25.72 6.21 18.12 20.37 24.42 8.29 4.61 5.00
Price to Revenue (P/Rev)		 3.43 2.82 2.19 1.60 0.97 1.70 2.45 3.64 2.13 1.10 1.09
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 12,088.71 45.39 17.24 23.30
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 2.20% 5.80% 4.29%
Enterprise Value to Invested Capital (EV/IC)		 1.80 1.69 1.44 1.20 0.79 1.33 2.05 3.11 1.80 0.91 0.81
Enterprise Value to Revenue (EV/Rev)		 3.74 3.09 2.44 1.82 1.18 1.86 2.56 3.72 2.15 1.13 1.04
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 154.52 32.99 13.58 6.06 6.20
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 58.75 19.78 8.41 9.23
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3,078.51 27.24 11.95 13.78
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 22.16 26.51 25.79 34.46 12.57 8.41 5.55
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 37.31 52.43 35.03 140.31 16.26 12.70 8.15
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.29 0.30 0.30 0.31 0.28 0.28 0.24 0.23 0.20 0.18 0.15
Long-Term Debt to Equity		 0.27 0.27 0.27 0.29 0.26 0.25 0.21 0.20 0.17 0.16 0.14
Financial Leverage		 -0.20 -0.22 -0.18 -0.20 0.17 0.15 0.13 0.12 0.09 0.08 0.03
Leverage Ratio		 1.26 1.25 1.24 1.25 1.46 1.44 1.42 1.42 1.42 1.36 1.33
Compound Leverage Factor		 1.35 1.63 1.72 1.46 0.88 2.29 0.76 0.70 1.23 -2.02 29.21
Debt to Total Capital		 22.26% 22.82% 22.86% 23.56% 21.90% 21.84% 19.25% 18.69% 16.68% 15.26% 12.66%
Short-Term Debt to Total Capital		 1.23% 2.20% 2.10% 1.34% 1.34% 2.22% 2.23% 2.19% 2.76% 1.31% 0.83%
Long-Term Debt to Total Capital		 21.03% 20.61% 20.76% 22.22% 20.57% 19.62% 17.01% 16.49% 13.91% 13.95% 11.83%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 77.74% 77.18% 77.14% 76.44% 78.10% 78.16% 80.76% 81.31% 83.32% 84.74% 87.34%
Debt to EBITDA		 -1.42 -1.73 -1.88 -1.52 -3.91 -6.01 16.36 2.28 1.48 1.17 1.15
Net Debt to EBITDA		 -0.88 -0.98 -1.07 -0.82 -2.32 -2.94 6.81 0.69 0.13 0.16 -0.31
Long-Term Debt to EBITDA		 -1.35 -1.56 -1.71 -1.43 -3.67 -5.40 14.46 2.01 1.24 1.07 1.08
Debt to NOPAT		 -1.96 -2.12 -2.20 -1.78 -3.42 -4.31 -10.54 212.29 2.97 2.30 2.56
Net Debt to NOPAT		 -1.21 -1.20 -1.26 -0.97 -2.03 -2.11 -4.39 64.83 0.27 0.31 -0.69
Long-Term Debt to NOPAT		 -1.85 -1.92 -2.00 -1.68 -3.21 -3.87 -9.32 187.36 2.48 2.11 2.39
Altman Z-Score		 2.53 2.46 2.13 1.56 1.15 1.90 3.29 5.24 3.32 2.19 2.18
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.04 2.88 3.07 3.23 2.89 2.82 2.57 3.05 3.04 5.37 5.58
Quick Ratio		 2.80 2.68 2.64 2.93 2.77 2.69 2.38 2.80 2.87 4.99 5.03
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -105 -96 -91 -88 12 9.43 13 4.29 12 -0.32 5.07
Operating Cash Flow to CapEx		 0.00% 1,384.31% 920.00% 1,946.74% 165.00% 4,600.00% 10,365.91% 32,020.00% 0.00% -2,223.81% 24,602.86%
Free Cash Flow to Firm to Interest Expense		 0.00 -62.32 -59.58 -57.64 7.92 7.27 8.24 3.72 9.34 -0.28 4.50
Operating Cash Flow to Interest Expense		 0.00 1.37 0.51 1.18 0.13 2.98 2.85 2.77 5.72 -0.40 7.64
Operating Cash Flow Less CapEx to Interest Expense		 0.00 1.27 0.46 1.11 0.05 2.91 2.82 2.77 5.88 -0.42 7.61
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.45 0.51 0.57 0.61 0.52 0.55 0.61 0.65 0.63 0.64 0.59
Accounts Receivable Turnover		 2.45 3.26 3.89 3.74 2.47 3.02 3.61 3.74 2.88 3.32 3.38
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 499.37 526.79 533.41 568.35 616.23 622.87 686.87 782.19 854.91 835.37 770.73
Accounts Payable Turnover		 15.16 20.68 16.67 19.15 14.94 13.42 15.03 15.86 18.90 9.98 15.99
Days Sales Outstanding (DSO)		 149.04 111.80 93.88 97.61 147.51 120.81 101.11 97.58 126.69 110.01 107.86
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 24.08 17.65 21.90 19.06 24.43 27.21 24.28 23.02 19.31 36.58 22.83
Cash Conversion Cycle (CCC)		 124.96 94.15 71.99 78.55 123.09 93.60 76.83 74.57 107.38 73.43 85.03
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 149 143 141 134 136 132 131 131 131 133 126
Invested Capital Turnover		 0.71 0.81 0.86 0.95 0.65 0.69 0.77 0.83 0.82 0.81 0.77
Increase / (Decrease) in Invested Capital		 97 93 88 82 -12 -11 -10 -2.77 -5.83 0.60 -5.13
Enterprise Value (EV)		 267 241 203 161 108 176 269 408 235 121 102
Market Capitalization		 245 221 183 141 89 160 257 399 233 118 107
Book Value per Share		 $6.97 $6.75 $6.63 $6.25 $6.40 $6.29 $6.45 $6.59 $6.88 $6.91 $6.99
Tangible Book Value per Share		 $0.77 ($0.24) ($0.26) $0.30 $0.78 $0.48 $0.68 $0.88 $1.51 $1.36 $1.15
Total Capital		 163 159 157 150 150 149 148 150 154 153 150
Total Debt		 36 36 36 35 33 32 28 28 26 23 19
Total Long-Term Debt		 34 33 33 33 31 29 25 25 21 21 18
Net Debt		 22 21 20 19 19 16 12 8.58 2.31 3.17 -5.09
Capital Expenditures (CapEx)		 -0.77 0.15 0.09 0.09 0.12 0.08 0.04 0.01 -0.21 0.02 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 25 20 19 18 24 20 20 22 24 28 22
Debt-free Net Working Capital (DFNWC)		 38 35 34 34 37 37 36 41 48 48 46
Net Working Capital (NWC)		 36 32 31 32 35 33 33 38 43 46 44
Net Nonoperating Expense (NNE)		 -3.51 3.38 1.38 3.13 -0.05 0.73 1.32 0.74 0.74 0.77 0.64
Net Nonoperating Obligations (NNO)		 22 21 20 19 19 16 12 8.58 2.31 3.17 -5.09
Total Depreciation and Amortization (D&A)		 1.22 1.25 1.26 1.28 1.38 1.27 1.51 1.26 1.40 1.42 1.34
Debt-free, Cash-free Net Working Capital to Revenue		 34.39% 25.46% 23.26% 20.73% 25.98% 21.29% 18.84% 19.76% 22.24% 25.65% 21.88%
Debt-free Net Working Capital to Revenue		 53.76% 44.86% 41.24% 39.02% 40.51% 38.85% 34.68% 37.58% 43.60% 44.44% 46.31%
Net Working Capital to Revenue		 50.96% 40.39% 37.27% 36.75% 38.34% 35.35% 31.53% 34.57% 39.71% 42.58% 45.04%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.25) ($0.38) ($0.22) ($0.50) $0.00 ($0.12) $0.08 $0.04 $0.28 ($0.03) ($0.04)
Adjusted Weighted Average Basic Shares Outstanding		 17.12M 18.17M 18.26M 18.32M 18.29M 18.47M 18.51M 18.58M 18.56M 18.76M 18.79M
Adjusted Diluted Earnings per Share		 ($0.25) ($0.38) ($0.22) ($0.50) $0.00 ($0.12) $0.08 $0.04 $0.27 ($0.03) ($0.04)
Adjusted Weighted Average Diluted Shares Outstanding		 17.12M 18.17M 18.26M 18.32M 18.29M 18.47M 19.02M 19.46M 19.00M 18.76M 18.79M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 18.27M 18.32M 0.00 0.00 18.50M 18.57M 18.64M 18.76M 18.77M 18.84M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.66 -3.52 -2.62 -0.75 2.54 -1.47 2.85 1.52 5.76 0.28 -0.06
Normalized NOPAT Margin		 -26.99% -17.88% -13.95% -3.52% 7.87% -6.71% 9.77% 5.84% 17.86% 1.40% -0.30%
Pre Tax Income Margin		 -41.50% -33.29% -27.09% -46.65% 6.83% -14.92% 5.87% 4.02% 23.18% -3.25% -5.35%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 -3.25 -2.40 -5.59 2.33 -1.59 2.01 1.83 6.96 0.38 -0.04
NOPAT to Interest Expense		 0.00 -2.28 -1.72 -3.93 -0.08 -1.13 1.78 1.32 4.64 0.24 -0.05
EBIT Less CapEx to Interest Expense		 0.00 -3.35 -2.46 -5.65 2.25 -1.66 1.99 1.82 7.12 0.36 -0.08
NOPAT Less CapEx to Interest Expense		 0.00 -2.38 -1.77 -3.99 -0.16 -1.20 1.75 1.31 4.81 0.22 -0.09
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -42.82% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

OptimizeRx (NASDAQ: OPRX) is showing a sharp turnaround in profitability, but the latest quarter also highlights renewed pressure on cash flow and leverage. In Q1 2026, the company reported a small net loss, compared with a profit in Q4 2025 and a modest profit in Q3 2025. Revenue also declined sequentially from the prior two quarters, while debt remains a meaningful part of the balance sheet.

  • Gross profit remained solid in Q1 2026 at $14.9 million on $19.8 million of revenue, showing the business still generates healthy gross margins.
  • The company has proven it can return to profitability: OptimizeRx posted net income of $5.0 million in Q4 2025 and $0.8 million in Q3 2025 after several loss-making quarters in 2024 and early 2025.
  • Operating cash flow was strong in late 2025, including $7.1 million in Q4 2025 and $3.2 million in Q3 2025, suggesting the core business can still produce cash when performance improves.
  • Cash balance was still adequate at $20.2 million at the end of Q1 2026, up slightly from $19.5 million in Q3 2025.
  • Quarterly debt repayment continues, indicating management is still working to reduce borrowings over time.
  • Revenue is choppy: Q1 2026 revenue of $19.8 million was below $32.2 million in Q4 2025, $26.1 million in Q3 2025, and $29.2 million in Q2 2025, but in line with the broader pattern of variability seen over the last year.
  • Balance sheet composition is dominated by intangibles and goodwill, with goodwill of $70.9 million and intangible assets of $33.2 million in Q1 2026, so a large portion of assets is not hard tangible value.
  • Accounts receivable remains large at $31.99 million, which is common in this type of business but still worth watching for collection efficiency.
  • There was a recent rise in common equity versus Q3 2025, but retained earnings remain deeply negative at -$79.7 million, reflecting the company’s long history of losses.
  • Q1 2026 returned to a net loss of $495,000, and operating income was only $396,000, showing profitability is still fragile.
  • Operating cash flow turned negative in Q1 2026 at -$467,000 after being strongly positive in the prior two quarters.
  • Debt is still elevated: the company had $2.0 million of short-term debt and $21.3 million of long-term debt at the end of Q1 2026.
  • Interest expense remains a major drag, at $1.16 million in Q1 2026 versus only $396,000 of operating income, which makes earnings highly sensitive to financing costs.
  • Working-capital usage hurt cash generation in Q1 2026, with changes in operating assets and liabilities reducing cash by $3.2 million.

Bottom line: OptimizeRx has shown it can swing back to profitability and generate cash, but the latest quarter suggests that momentum has not yet been sustained. Investors should watch for whether revenue stabilizes and whether the company can restore positive operating cash flow while continuing to manage debt.

08/20/26 05:03 AM ETAI Generated. May Contain Errors.

OptimizeRx Financials - Frequently Asked Questions

According to the most recent income statement we have on file, OptimizeRx's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

OptimizeRx's net income appears to be on an upward trend, with a most recent value of $5.13 million in 2025, falling from -$595.14 thousand in 2015. The previous period was -$20.11 million in 2024. Find out what analysts predict for OptimizeRx in the coming months.

OptimizeRx's total operating income in 2025 was $11.69 million, based on the following breakdown:
  • Total Gross Profit: $73.60 million
  • Total Operating Expenses: $61.90 million

Over the last 10 years, OptimizeRx's total revenue changed from $3.60 million in 2015 to $109.43 million in 2025, a change of 2,941.0%.

OptimizeRx's total liabilities were at $48.62 million at the end of 2025, a 10.2% decrease from 2024, and a 1,342.1% increase since 2015.

In the past 10 years, OptimizeRx's cash and equivalents has ranged from $5.12 million in 2017 to $84.68 million in 2021, and is currently $23.37 million as of their latest financial filing in 2025.

Over the last 10 years, OptimizeRx's book value per share changed from 0.31 in 2015 to 6.88 in 2025, a change of 2,133.1%.


Related Companies

Financial statements for NASDAQ:OPRX last updated on 8/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
This tiny launch company operates next to SpaceX and Blue Origin
A small publicly traded company operates a specialized launch vehicle fleet inside the secure perimeter of Ken...
Freedom Financial | Sponsoredtc pixel
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel